Lubiprostone

• Description :

  Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397) -induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research[1][2][3].

• Product Name Alternative :

  RU-0211; SPI-0211

• UNSPSC :

  12352211

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  CFTR; Chloride Channel; Glutathione Peroxidase; NO Synthase; TNF Receptor

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/lubiprostone.html

• Purity :

  99.09

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(C(F)(F)CCCC)CC[C@@H]([C@@H](C1)O)[C@H](C1=O)CCCCCCC(O)=O

• Molecular Formula :

  C20H32F2O5

• Molecular Weight :

  390.46

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Ao M, et al., Lubiprostone activates Cl- secretion via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84. Dig Dis Sci. 2011 Feb;56 (2) :339-51.|[2]Kim MY, et al., Lubiprostone significantly represses fatty liver diseases via induction of mucin and HDL release in mice. Life Sci. 2022 Dec 15;311 (Pt A) :121176.|[3]Hayashi S, et al., Lubiprostone prevents nonsteroidal anti-inflammatory drug-induced small intestinal damage by suppressing the expression of inflammatory mediators via EP4 receptors. J Pharmacol Exp Ther. 2014 Jun;349 (3) :470-9.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [136790-76-6]